The effectivness of entecavir in chronic hepatitis B in patients resistant to lamivudine and adefovir

Background/aims: Entecavir, a nucleoside analog, is a new medication that is active against both lamivudine- and adefovir-resistant HBV. The aim of this study was to investigate the effectiveness of entecavir in patients with chronic hepatitis B resistant to lamivudine and/or adefovir therapy in patients from United Arab Emirates. Methods: In an observational prospective study, we followed 36 patients with chronic hepatitis B who received either lamivudine or adefovir monotherapy or combination therapy. Some of these patients were treated with peginterferon alfa 2a in the past. Twelve patients became resistant t…